ALLIANCE PHARMA PLC — Director's Dealing 2013

Jun 21, 2013

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6225H

Alliance Pharma PLC

21 June 2013

	21 June 2013

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Director Shareholding

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, was notified today that John Dawson, Chief Executive, has today sold 460,000 ordinary shares of 1p each in the Company ("Ordinary Shares") at a price of 35 pence.

Following this transaction, Mr Dawson has a beneficial interest in 39,576,402 Ordinary Shares representing 15.75% of the Company's issued share capital and a non-beneficial interest in 20,000,000 Ordinary Shares representing 7.96% of the Company's issued share capital.

For further information:

### Alliance Pharma plc	### + 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
www.alliancepharma.co.uk
### Buchanan	### + 44 (0) 20 7466 5000
Mark Court / Fiona Henson / Sophie Cowles
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Oliver Cardigan / Freddie Barnfield
Corporate Broking: David Poutney

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 products and continues to explore opportunities to expand the range.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSFBMJTMBITBAJ